Feedback
Settings

Settings

Goto Application

35,367 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:G01N33/569

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 3,537
1.WO/2025/139807MONOCLONAL ANTIBODY AGAINST CAPSULAR POLYSACCHARIDE OF KLEBSIELLA PNEUMONIAE SEROTYPE K64, HYBRIDOMA CELL LINE THEREOF AND USE THEREOF
WO - 03.07.2025
Int.Class C07K 16/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
12against material from bacteria
 Appl.No PCT/CN2024/138668 Applicant SHANGHAI BOFAN BIOTHERAPEUTICS CO., LTD. Inventor HE, Ping
A monoclonal antibody against the capsular polysaccharide of Klebsiella pneumoniae serotype K64, a hybridoma cell line thereof and the use thereof. The sequence information of the monoclonal antibody against the capsular polysaccharide of Klebsiella pneumoniae serotype K64 is as set forth in SEQ NO: 1-SEQ NO: 56, and the accession numbers of the hybridoma cell lines are CCTCC: C2023365, CCTCC: C2023366, CCTCC: C2023367, CCTCC: C2024340, CCTCC: C2024341, CCTCC: C2024342 and CCTCC: C2024343, respectively. The provided monoclonal antibody against the capsular polysaccharide of Klebsiella pneumoniae can specifically bind to the capsular polysaccharide of Klebsiella pneumoniae, which is beneficial for the typing of Klebsiella pneumoniae in clinical practice. Both in vivo and in vitro animal experiments have demonstrated that the monoclonal antibody against the capsular polysaccharide of Klebsiella pneumoniae has excellent effects in preventing and treating infections caused by Klebsiella pneumoniae serotype K64, which provides a way to solve the problems of Klebsiella pneumoniae infections and multi-drug resistance, has significant significance in the prevention, diagnosis and treatment of Klebsiella pneumoniae infections, and has an important value for the development of new-generation drugs against Klebsiella pneumoniae.
2.WO/2025/143857METABOLOME MARKER FOR DIFFERENTIAL DIAGNOSIS OF MYCOBACTERIUM AVIUM COMPLEX OR MYCOBACTERIUM TUBERCULOSIS INFECTIOUS DISEASE
WO - 03.07.2025
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
 Appl.No PCT/KR2024/021253 Applicant UIF (UNIVERSITY INDUSTRY FOUNDATION), YONSEI UNIVERSITY Inventor SHIN, Sung Jae
The present invention relates to a composition for differential diagnosis of a Mycobacterium avium complex (MAC) or Mycobacterium tuberculosis (MTb) infectious disease using lipid metabolites, amino acids, and/or amino acid derivatives as markers. The present invention applies the metabolites as markers for predicting, with high accuracy, Mycobacterium avium complex and Mycobacterium tuberculosis infection diseases, which are two diseases having similar clinical expression characteristics, thereby enabling rapid discrimination of the diseases. Accordingly, a patient-customized treatment strategy can be established at an early stage, and thus, the present invention can be helpfully used to significantly improve the survival rate of a patient.
3.WO/2025/141289A BIOSENSOR FOR REAL-TIME MONITORING OF CLOSTRIDIAL NEUROTOXIN PRODUCTION
WO - 03.07.2025
Int.Class G01N 33/542
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
536with immune complex formed in liquid phase
542with steric inhibition or signal modification, e.g. fluorescent quenching
 Appl.No PCT/GB2024/053207 Applicant IPSEN BIOPHARM LIMITED Inventor OLUGHU, Williams
The present invention is a biosensor for real-time monitoring of clostridial neurotoxin production during a bacterial fermentation process. The biosensor comprises a surface for performing the analysis of binding events and kinetics, and onto which is immobilised a binding substrate comprising: a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a binding region that specifically binds to the clostridial neurotoxin; wherein said binding region being positioned between the donor fluorophore and the acceptor such that, following activation of the donor fluorophore, resonance energy transfer is exhibited between said donor fluorophore and said acceptor.
4.WO/2025/143714DIAGNOSTIC KIT FOR BOVINE DIARRHEA-CAUSING VIRUS
WO - 03.07.2025
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
 Appl.No PCT/KR2024/020949 Applicant BOREDA BIOTECH Inventor CHOI, Dong Ok
The present invention relates to a diagnostic kit for bovine viral diarrhea virus (BVDV), which enables rapid on-site identification and diagnosis of BVDV1 and BVDV2, which are genotypes of the BVD virus that are pathogens causing bovine diarrhea, within a short time of approximately 15 minutes.
5.WO/2025/141913METHOD FOR ANALYZING TRACE SUBSTANCE
WO - 03.07.2025
Int.Class C12Q 1/32
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
26involving oxidoreductase
32involving dehydrogenase
 Appl.No PCT/JP2024/023024 Applicant WASEDA UNIVERSITY Inventor ITO Etsuro
This method for analyzing a trace substance involves: a step A for separating a trace substance with a separation member including a porous material; a step B for binding, to the separated trace substance, an enzyme-labeled antibody or an enzyme-labeled nucleic-acid probe, wherein the enzyme-labeled antibody includes an enzyme α and an antibody specific to the trace substance, and the enzyme-labeled nucleic-acid probe includes an enzyme α and a nucleic-acid probe specific to the trace substance; a step C for making the enzyme α of the enzyme-labeled antibody or the enzyme α of the enzyme-labeled nucleic-acid probe act on a compound β which is a substrate of the enzyme α to produce a compound γ which is a substrate of a dehydrogenase; a step D for producing thio-NAD(P)H through an enzyme cycling reaction using the produced compound γ, a dehydrogenase, NAD(P)H, and thio-NAD(P); and a step E for detecting the trace substance by the produced thio-NAD(P)H.
6.WO/2025/132472METHOD FOR DETECTING VIABLE MICROORGANISMS WHICH ARE POTENTIALLY PRESENT IN A SAMPLE OF CELLULAR PRODUCTS
WO - 26.06.2025
Int.Class C12Q 1/04
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
02involving viable microorganisms
04Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
 Appl.No PCT/EP2024/086952 Applicant BIOMERIEUX Inventor DE LA FOATA, Corinne
The present invention relates to a method for isolating viable microorganisms which are potentially present in a sample comprising 106 to 108 immune cells or progenitor cells thereof, the method comprising the following steps: - bringing the sample into contact with: • a lysing composition comprising o a lysis buffer comprising a non-ionic detergent at a concentration of between 0.004% and 0.050% of the reaction volume o and/or a lysis solution comprising a saponin at a concentration of between 0.03% and 4% of the reaction volume; • an endonuclease for digesting the nucleic acids released by the action of the lysing composition; • an endopeptidase acting at a pH of between 7 and 8; - separating the viable microorganisms which are potentially present in the sample by filtering the sample through a filter, the pores of which have a diameter of between 0.30 and 0.50 μm. The present invention also relates to the associated solid-phase cytometry detection method.
7.20250208133SENESCENT CELL SURFACE MARKERS
US - 26.06.2025
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
 Appl.No 18835014 Applicant SENS RESEARCH FOUNDATION Inventor Amit SHARMA

Senescent cells are implicated in aspects of age-related decline in health and may contribute to certain diseases. Embodiments include biomarkers that are unique to senescent cells. The biomarkers have diagnostic and therapeutic uses for senescence-associated diseases and disorders. Embodiments also include methods of distinguishing non-senescent cells from senescent cells based on the presence or absence of one or more of the biomarkers. Senescent cells can be selectively labelled to detect an ailment in a subject, devise a treatment and/or determine the effectiveness of a senolytic agent. Embodiments also include methods of removing senescent cells from a patient or an affected tissue. The method can target senescent cells by inhibiting lysosomal exocytosis.

8.20250208136Peptides and combinations of peptides for use in immunotherapy against oropharyngeal squamous cell carcinoma (OPSCC) and other cancers
US - 26.06.2025
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
 Appl.No 19039730 Applicant Eberhard Karls Universität Tübingen Medizinische Fakultät Inventor Simon Laban

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular of oropharyngeal squamous cell carcinoma (OPSCC). The present invention furthermore relates to tumor-associated T-cell peptide epitopes that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

9.20250208134DEVICE AND METHOD FOR CHARACTERIZATION OF BIOLOGICAL CELLS
US - 26.06.2025
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
 Appl.No 18987869 Applicant IMEC VZW Inventor Willem VAN ROY

According to an aspect of the present inventive concept there is provided a device for characterizing biological cells comprising: a flow channel passing a flow of liquid carrying the biological cells to be characterized, the flow channel comprises at least one zone associated with a cell category; at least one detector to detect information representing the biological cells passing the at least one zone; a processor configured to receive and process the information by: dividing each zone into segments; identifying candidate biological cells; identifying tracks from each of the candidate biological cells; for each track, determining a set of transit times, wherein each transit time represents a transit time of the candidate biological cell through a segment; for each candidate biological cell, processing the set of transit times for characterizing the candidate biological cell by determining whether the candidate biological cell is a biological cell belonging to an associated biological cell category of each respective zone.

10.20250208132A DEVICE AND A METHOD FOR ANALYZING BIOLOGICAL CELLS
US - 26.06.2025
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
 Appl.No 18987770 Applicant IMEC VZW Inventor Tim STAKENBORG

According to an aspect of the present inventive concept there is provided a device for analyzing biological cells comprising: a flow channel passing a flow of liquid carrying the biological cells to be analyzed, the flow channel comprises at least one zone associated with a cell category; at least one detector to detect information representing the biological cells passing the at least one zone; a processor configured to receive and process the information by: identifying candidate biological cells; identifying tracks from the candidate biological cells; identifying candidate modified movements as events in each track; determining event related information associated with the event, the event related information comprises at least a sensed property of the candidate biological cells and/or a property defining a relation between events of at least two tracks from candidate biological cells; identifying candidate non-specific modified movements among the candidate modified movements; and removing the candidate non-specific modified movements from the candidate modified movements for each track.

# -